Fingolimod Phase III Trial In PPMS Fails To Meet Main Goal

December 1, 2014 6:41 AM

11 0

Swiss pharmaceutical giant Novartis AG (NVS: Quote) Monday announced that the Phase III INFORMS study in primary progressive multiple sclerosis or PPMS did not meet its primary endpoint.

PPMS is a disorder of the central nervous system or CNS which affects approximately 10% of the 2.3 million patients diagnosed with MS worldwide. It is a distinct disease form, different from relapsing MS in terms of its basic disease process, near-absence of acute relapses and fewer active MRI lesio...

Read more

To category page